|
ES2235331T3
(es)
*
|
1997-05-28 |
2005-07-01 |
Aventis Pharmaceuticals Inc |
Compuestos quinolina y quinoxalina que inhiben el factor de crecimiento derivado de plaquetas y/o tirosina quinasas p561ck.
|
|
US6180632B1
(en)
|
1997-05-28 |
2001-01-30 |
Aventis Pharmaceuticals Products Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
|
US6245760B1
(en)
*
|
1997-05-28 |
2001-06-12 |
Aventis Pharmaceuticals Products, Inc |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
|
US6159978A
(en)
*
|
1997-05-28 |
2000-12-12 |
Aventis Pharmaceuticals Product, Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
|
US6506769B2
(en)
|
1999-10-06 |
2003-01-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
|
US7101869B2
(en)
|
1999-11-30 |
2006-09-05 |
Pfizer Inc. |
2,4-diaminopyrimidine compounds useful as immunosuppressants
|
|
EP1309596B1
(en)
|
2000-08-11 |
2008-02-06 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
|
AR039127A1
(es)
|
2002-03-27 |
2005-02-09 |
Glaxo Group Ltd |
Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
|
|
DE10237423A1
(de)
*
|
2002-08-16 |
2004-02-19 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
NZ544331A
(en)
|
2003-07-22 |
2010-03-26 |
Arena Pharm Inc |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
|
|
CN1930128A
(zh)
|
2004-01-16 |
2007-03-14 |
惠氏公司 |
受体酪氨酸激酶抑制剂的喹啉中间体及其合成
|
|
TW200902008A
(en)
|
2007-05-10 |
2009-01-16 |
Smithkline Beecham Corp |
Quinoxaline derivatives as PI3 kinase inhibitors
|
|
EP2254564A1
(en)
|
2007-12-12 |
2010-12-01 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
|
WO2009123714A2
(en)
|
2008-04-02 |
2009-10-08 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
EP2241557A1
(de)
|
2009-04-02 |
2010-10-20 |
Æterna Zentaris GmbH |
Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen
|
|
WO2011026579A1
(en)
|
2009-09-04 |
2011-03-10 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
|
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
|
CN101823998B
(zh)
*
|
2010-05-05 |
2015-03-25 |
江苏利田科技股份有限公司 |
一种反应器耦合模拟移动床乙氧基喹啉清洁生产工艺
|
|
ES2553771T3
(es)
|
2010-10-08 |
2015-12-11 |
Nivalis Therapeutics, Inc. |
Nuevos compuestos de quinolina sustituidos como inhibidores de la S-nitrosoglutatión reductasa
|
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
|
JP5990187B2
(ja)
|
2010-12-16 |
2016-09-07 |
ニヴァリス・セラピューティクス・インコーポレーテッド |
Ｓ−ニトロソグルタチオン還元酵素阻害薬としての新規な置換二環芳香族化合物
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
JP6166289B2
(ja)
|
2012-03-14 |
2017-07-19 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
置換イミダゾピリダジン
|
|
SG11201406584TA
(en)
|
2012-04-24 |
2014-11-27 |
Vertex Pharma |
Dna-pk inhibitors
|
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
RS62649B1
(sr)
|
2013-03-12 |
2021-12-31 |
Vertex Pharma |
Inhibitori dnk-pk
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
|
CA2914745A1
(en)
|
2013-06-11 |
2014-12-18 |
Bayer Pharma Aktiengesellschaft |
Prodrug derivatives of substituted triazolopyridines
|
|
KR102411227B1
(ko)
|
2013-10-17 |
2022-06-21 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
|
|
US10736900B2
(en)
|
2014-03-26 |
2020-08-11 |
Astex Therapeutics Ltd |
Combinations of an FGFR inhibitor and an IGF1R inhibitor
|
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
|
BR112016022056B1
(pt)
|
2014-03-26 |
2023-04-11 |
Astex Therapeutics Limited |
Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
TWI719960B
(zh)
|
2015-02-10 |
2021-03-01 |
英商阿斯迪克治療公司 |
新穎組成物
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
CA2976790C
(en)
|
2015-02-20 |
2024-02-27 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
JP2018516992A
(ja)
|
2015-06-12 |
2018-06-28 |
アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ |
レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
|
|
CN108472285A
(zh)
|
2015-07-15 |
2018-08-31 |
阿速万科学有限责任公司 |
用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
|
|
US10399946B2
(en)
|
2015-09-10 |
2019-09-03 |
Laurel Therapeutics Ltd. |
Solid forms of an S-Nitrosoglutathione reductase inhibitor
|
|
WO2017050865A1
(en)
|
2015-09-23 |
2017-03-30 |
Janssen Pharmaceutica Nv |
Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
|
|
HUE050567T2
(hu)
|
2015-09-23 |
2020-12-28 |
Janssen Pharmaceutica Nv |
Triciklusos heterociklusok rák kezelésére
|
|
MX394860B
(es)
|
2016-09-27 |
2025-03-24 |
Vertex Pharma |
Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
KR102956194B1
(ko)
|
2018-05-04 |
2026-04-23 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
MX2022006691A
(es)
|
2019-12-04 |
2022-09-19 |
Incyte Corp |
Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|